Also known as: α1-antitrypsin Serpin family A member 1 Alpha1 proteinase inhibitor A1PI A1AT
Alfa1 antitrypsin is indicated for:
Population group: both men and women, only adults (18 - 65 years old)
Alpha-1 antitrypsin is indicated for maintenance treatment, to slow the progression of emphysema in adults with documented severe alpha1-proteinase inhibitor deficiency (e.g. genotypes PiZZ, PiZ(null), Pi(null,null), PiSZ). Patients are to be under optimal pharmacologic and non-pharmacologic treatment and show evidence of progressive lung disease (e.g. lower forced expiratory volume per second (FEV1) predicted, impaired walking capacity or increased number of exacerbations) as evaluated by a healthcare professional experienced in the treatment of alpha1-proteinase inhibitor deficiency.
For this indication, competent medicine agencies globally authorize below treatments (click for details):